SCHEDULE 13G/A: BlackRock Discloses 12.1% Stake in Neurocrine Biosciences
Beneficial Ownership Report
BlackRock, Inc. has filed an amended Schedule 13G, revealing a beneficial ownership of 12.1% in Neurocrine Biosciences Inc.'s common stock as of March 31, 2025.
Summary
- BlackRock, Inc. reported beneficial ownership of 12,052,271 shares of Neurocrine Biosciences Inc. common stock.
- This ownership represents 12.1% of the total outstanding common stock of Neurocrine Biosciences Inc.
- BlackRock holds sole voting power over 11,506,267 shares and sole dispositive power over 12,052,271 shares.
- The shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing the control of the issuer.
- The filing is an Amendment No. 13 to the Schedule 13G, indicating previous filings by BlackRock regarding its stake in Neurocrine Biosciences.
- BlackRock Fund Advisors, a subsidiary of BlackRock, Inc., beneficially owns 5% or greater of the outstanding shares.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership, not containing performance data or forward-looking statements that would indicate a positive or negative sentiment. It is neutral in tone and content.
Positives
- The disclosure of a significant stake by a major institutional investor like BlackRock can be viewed positively, indicating confidence in the company's long-term prospects.
- BlackRock's holding is for investment purposes in the ordinary course of business, suggesting a passive, long-term investment rather than an activist stance.
Risks
- The document does not detail specific risks related to Neurocrine Biosciences' operations or financial health, as it is a beneficial ownership report.
Future Outlook
The document does not contain forward-looking statements or guidance regarding Neurocrine Biosciences' future performance or BlackRock's future investment intentions beyond the current beneficial ownership.
Industry Context
This filing reflects a standard disclosure by a large asset manager, BlackRock, regarding its passive investment in a biotechnology company, Neurocrine Biosciences. Such institutional holdings are common in the biotech sector, where long-term investment in companies with promising pipelines is typical.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Power of Attorney Update | BlackRock, Inc. updated its Power of Attorney, revoking the previous one dated April 30, 2023, and appointing new attorneys-in-fact for SEC and other regulatory filings. | 2025-01-21 | Streamlines the process for BlackRock to comply with various ownership and control-person reporting requirements across its subsidiaries and affiliates. |
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional investor's stake, which can influence market perception and liquidity.
- Management: Awareness of a large, passive institutional holder, which typically does not seek to influence control.
Key Dates
| Date | Description |
|---|---|
| 2023-04-30 | Previous Power of Attorney date, which was revoked by the new one. |
| 2025-01-21 | Date of execution for the current Power of Attorney granted by BlackRock, Inc. |
| 2025-03-31 | Date of event which required the filing of this statement (reporting period end). |
| 2025-04-28 | Date the Schedule 13G Amendment No. 13 was signed and filed. |
Keywords
BlackRock, Neurocrine Biosciences, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, SEC Filing, Investment Management, Biotechnology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.